Apollomics (APLM) Competitors $5.92 -0.08 (-1.25%) Closing price 03:59 PM EasternExtended Trading$5.95 +0.03 (+0.49%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. SCYX, DYAI, COEP, TPST, CVKD, TENX, ALXO, CARA, CYTH, and BCABShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include SCYNEXIS (SCYX), Dyadic International (DYAI), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), Cadrenal Therapeutics (CVKD), Tenax Therapeutics (TENX), ALX Oncology (ALXO), Cara Therapeutics (CARA), Cyclo Therapeutics (CYTH), and BioAtla (BCAB). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Its Competitors SCYNEXIS Dyadic International Coeptis Therapeutics Tempest Therapeutics Cadrenal Therapeutics Tenax Therapeutics ALX Oncology Cara Therapeutics Cyclo Therapeutics BioAtla SCYNEXIS (NASDAQ:SCYX) and Apollomics (NASDAQ:APLM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, earnings, valuation, dividends, profitability and media sentiment. Is SCYX or APLM more profitable? Apollomics has a net margin of 0.00% compared to SCYNEXIS's net margin of -1,030.04%. Apollomics' return on equity of 0.00% beat SCYNEXIS's return on equity.Company Net Margins Return on Equity Return on Assets SCYNEXIS-1,030.04% -53.47% -32.86% Apollomics N/A N/A N/A Which has higher earnings and valuation, SCYX or APLM? SCYNEXIS has higher revenue and earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSCYNEXIS$3.75M7.91-$21.29M-$0.56-1.36Apollomics$1.49M4.37-$53.86MN/AN/A Do insiders & institutionals hold more shares of SCYX or APLM? 54.4% of SCYNEXIS shares are owned by institutional investors. Comparatively, 19.1% of Apollomics shares are owned by institutional investors. 4.9% of SCYNEXIS shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media favor SCYX or APLM? In the previous week, Apollomics had 1 more articles in the media than SCYNEXIS. MarketBeat recorded 2 mentions for Apollomics and 1 mentions for SCYNEXIS. SCYNEXIS's average media sentiment score of 1.87 beat Apollomics' score of 0.62 indicating that SCYNEXIS is being referred to more favorably in the media. Company Overall Sentiment SCYNEXIS Very Positive Apollomics Positive Which has more volatility & risk, SCYX or APLM? SCYNEXIS has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500. Comparatively, Apollomics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. SummarySCYNEXIS beats Apollomics on 7 of the 11 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APLM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.52M$2.93B$5.57B$9.32BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.5028.6419.75Price / Sales4.37267.15432.34182.50Price / CashN/A43.1536.0257.96Price / Book1.327.768.235.67Net Income-$53.86M-$55.11M$3.24B$257.98M7 Day Performance2.86%1.03%0.05%0.56%1 Month Performance-7.70%8.54%5.65%8.88%1 Year Performance-70.67%-2.26%26.57%14.24% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics0.6879 of 5 stars$5.93-1.3%N/A-69.8%$6.52M$1.49M0.0045Gap DownSCYXSCYNEXIS1.0662 of 5 stars$0.72-2.0%N/A-65.1%$27.62M$2.63M-1.2660Positive NewsDYAIDyadic International3.1237 of 5 stars$0.91-2.9%$6.00+557.2%-31.0%$27.55M$3.34M-4.587Positive NewsCOEPCoeptis Therapeutics0.5054 of 5 stars$7.85+4.1%N/A+62.4%$26.49M$62.87K-1.352News CoverageTPSTTempest Therapeutics2.3476 of 5 stars$7.12+0.6%$30.00+321.3%-76.8%$26.20MN/A-0.4020Positive NewsCVKDCadrenal Therapeutics2.9283 of 5 stars$13.38+3.1%$32.00+139.2%N/A$25.53MN/A-1.404Positive NewsGap DownTENXTenax Therapeutics1.6644 of 5 stars$5.94+2.2%$17.50+194.6%+77.1%$24.64MN/A-2.399Positive NewsALXOALX Oncology3.5465 of 5 stars$0.46+2.5%$3.30+625.3%-94.2%$24.35MN/A-0.1840CARACara Therapeutics0.2861 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading VolumeCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809BCABBioAtla2.0361 of 5 stars$0.39+2.1%$5.00+1,169.0%-77.5%$23.19M$11M-0.3360 Related Companies and Tools Related Companies SCYNEXIS Competitors Dyadic International Competitors Coeptis Therapeutics Competitors Tempest Therapeutics Competitors Cadrenal Therapeutics Competitors Tenax Therapeutics Competitors ALX Oncology Competitors Cara Therapeutics Competitors Cyclo Therapeutics Competitors BioAtla Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free APLM Stock Alerts